New York City, NY- Feel dizzy or even maybe a bit nauseous every time you put on a virtual reality device? There’s a pill for that. VIRMO is the capsule that promises to alleviate symptoms of nausea and dizziness to help keep users immersed for longer and better VR experiences. By taking two of the VIRMO pills 30 minutes before putting on a VR headset, VIRMO promises to be the Asprin of VR.

But maybe a pill that recently skipped FDA approval isn’t your thing. For those, researchers are diving deep into virtual reality experiences to craft solutions within the devices themselves.

Creating a VR experience that reduces occurrences of motion sickness begins with a deep understanding of the root causes. The feeling of motion sickness occurs when the input from your eyes contradicts the input from their inner ear, which tracks motion and balance. Often, this sensation will result in vertigo, nausea and other unpleasant symptoms for users. Current VR headsets have screens that are not sharp enough to mirror the viewer’s motion. So when these transitions don’t match the body’s expectation, or when the display doesn’t blur the background when a user focuses on a single object, problems occur.

LCD screens created by researchers at Stanford Computational Imaging may be the answer to ultimately eliminating VR vertigo for those who are prone to motion sickness while using VR devices. The researchers built a headset with LCDs in each of the lenses in order to project the images as they would normally appear in real life to create smoother transitions within the VR experience.

 

 

This Stanford-based project could create an entire new wave of accessible options for people with technological disabilities. Be sure to follow the Stanford team on their future ventures in next-generation computational imaging and display systems.

About the Author:

As Managing Director of Innovation for Syneos Health Communications, Leigh is responsible for shaping the company’s perspective on the next era of healthcare marketing. Through thought leadership, strategic innovation workshops and new products and capabilities, Leigh focuses on identifying marketing approaches that will fuel that new era and generate significant growth for clients. Leigh has worked with Fortune 1000 companies to craft their digital, mobile, social and CRM strategies for over 17 years. She’s worked for category-leading agencies in retail, public affairs, B2B technology, and higher education. Prior to moving to Syneos Health Communications, she had several leadership roles at one of our agencies, GSW. There, she founded an innovation practice fueled by the zeitgeist and spearheaded digital and innovation thinking across the business. Leigh has taken a special interest in complex healthcare products that can change lives in meaningful ways. She was recently a strategic lead on the 3rd largest launch in pharmaceutical history: Tecfidera. Before that she had keys roles with Eli Lilly Oncology, Abbott Nutrition, Amgen Cardiovascular, and Eli Lilly Diabetes. A critical part of Leigh’s work is trends and new ideas. Every year, she convenes a group of trend watchers from across our global network to identify the shifts most critical to healthcare marketers. Leigh is a sought-after writer and speaker. Recognized as one of the most inspiring people in the pharmaceutical industry by PharmaVoice, Leigh also was recognized as a Rising Star by the Healthcare Businesswomen's Association (HBA) for her overt passion, industry thought leadership and significant contributions in new business, strategy and mentoring.